Scholar Rock (SRRK) News
NASDAQ: SRRKHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
48.13-2.24 (-4.45%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SRRK news summary
We found 11 recent headlines mentioning Scholar Rock (SRRK): 0 in the past week and 8 in the past 30 days, most often from Nasdaq, Seeking Alpha, Business Wire. For price context, SRRK is down 4.45% at $48.13. The most recent story, "Scholar Rock (SRRK) Q3 2026 Earnings Call Transcript", was published by Nasdaq on Nov 10, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Scholar Rock headlines
- Scholar Rock (SRRK) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- What Scholar Rock (SRRK) Said on Its Q3 Earnings Call3 Beaten-Down Stocks With Rebound Potential This Earnings SeasonScholar Rock (NASDAQ:SRRK) reported $0.6 million in third-quarter revenue from initial shipments of its newly approved spinal muscular…Nasdaq
- Scholar Rock anticipates CHMP opinion in H1 2027 as it monetizes a $205M priority review voucherSeeking Alpha
- BioNTech to buy Scholar Rock Priority Review Voucher for $205MSeeking Alpha
- Scholar Rock Reports Third Quarter 2026 Financial Results and Recent Business HighlightsCAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular…Business Wire
- Scholar Rock Q3 2026 Earnings PreviewSeeking Alpha
- Wednesday 10/28 Insider Buying Report: LRN, SRRKBargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their…NasdaqLRN, SRRK
- Tuesday’s insider trading: Scholar Rock director buys $12 millionInvesting.com
- Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK) today announced that it will report third quarter 2026 financial results on Tuesday, November 10, 2026, before the financial markets…Business Wire
- FDA Drug Approvals In September 2026(RTTNews) - The U.S. Food and Drug Administration (FDA) approved 13 drugs in September 2026, spanning first-in-class therapies, treatments for rare diseases, and new options for patients with serious…NasdaqABBV, AZN, INCY, IONS
- Biotech Stocks Facing FDA Decision In September 2026(RTTNews) - As September ushers in the first hints of autumn, it also brings a packed FDA regulatory calendar.NasdaqBFRI, BMY, IONS, MIRM